Lysine Demethylase Inhibitor (17-AAG) Effect on Breast Cancer Cells (MCF7)

A tétel rövid nézete
dc.contributor.advisorSzabó, Gábor
dc.contributor.advisordeptBiofizikai és Sejtbiológiai Intézethu_HU
dc.contributor.authorMalkawi, Noor Khalid
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentBálint, Bálint László
dc.contributor.opponentdeptBiokémiai és Molekuláris Biológiai Intézethu_HU
dc.date.accessioned2022-06-14T13:23:24Z
dc.date.available2022-06-14T13:23:24Z
dc.date.created2022-06-01
dc.description.abstractHistone lysine demethylases (KDM4) subfamily genes that are also considered as protooncogenes have a role in switching the genes on and off in normal as well as cancer tissues. Breast cancer driver genes are induced after the overexpression of KDM4s due to removal of the repressive histone mark H3K9me3, with the concomitant activation of the estrogen receptor pathway leading to the formation of tumors in the breast tissue. The emergence of KDM4 inhibitors made it possible to use them to inhibit cancer growth. One example is Geldanamycin and its derivative 17-AAG (17-(Allylamino)-17- demethoxygeldanamycin) which are also Hsp90 inhibitors. We investigated this inhibitor in breast cancer cell lines (MCF7) and qualitatively analyzed its cellular toxicity.hu_HU
dc.description.correctorLB
dc.description.coursemolekuláris biológiahu_HU
dc.description.courselangangolhu_HU
dc.description.coursespecBiokémia-genomikahu_HU
dc.description.degreeMSc/MAhu_HU
dc.format.extent23hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/335334
dc.language.isoenhu_HU
dc.subjectKDM4 inhibitorshu_HU
dc.subject.dspaceDEENK Témalista::Biológiai tudományokhu_HU
dc.titleLysine Demethylase Inhibitor (17-AAG) Effect on Breast Cancer Cells (MCF7)hu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)